AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17606475 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 48
Study 17606475 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (1.5 mg)
Number of subjects: 48
Study 17606475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 16208149 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (20, 40, or 80 mg)
Number of subjects: 1039
Study 16208149 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg)
Number of subjects: 1039
Study 16208149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1039
Study 12356955 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reports by standardised patients (SPs) who presented unannounced to the physicians' clinics
Number of subjects: 20
Study 12356955 — intervention group
Group type: COMPARATOR
Intervention: Abstraction of the medical records generated during these visits
Number of subjects: 20
Study 12356955 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reports by standardised patients (SPs)
Number of subjects: 20
Study 12356955 — intervention group
Group type: COMPARATOR
Intervention: Abstraction of the medical records
Number of subjects: 20
Study 12356955 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual physician subjects
Number of subjects: 20
Study 10411366 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combination therapy (5 mg enalapril + 5 mg felodipine ER once daily)
Number of subjects: 217
Study 10411366 — intervention group
Group type: COMPARATOR
Intervention: Higher dose of monotherapy (10 mg enalapril once daily)
Number of subjects: 217
Study 7480492 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental groups (n = 101)
Number of subjects: 729
Study 7480492 — intervention group
Group type: EXPERIMENTAL
Intervention: General psychiatric patients (n = 64)
Number of subjects: 729
Study 7480492 — intervention group
Group type: EXPERIMENTAL
Intervention: General adult normative population (n = 564)
Number of subjects: 729
Study 1443507 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg ketamine racemate
Number of subjects: 30
Study 1443507 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg S-(+)-Ketamine
Number of subjects: 30
Study 1443507 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg S-(+)-Ketamine after 0.1 mg/kg midazolam premedication
Number of subjects: 30
Study 1443507 — intervention group
Group type: COMPARATOR
Intervention: ketamine racemate
Number of subjects: 30
Study 1443507 — intervention group
Group type: COMPARATOR
Intervention: S-(+)-Ketamine
Number of subjects: 30
Study 3550071 — intervention group
Group type: EXPERIMENTAL
Intervention: guanethidine
Number of subjects: 24
Study 3550071 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 29758155 — intervention group
Group type: EXPERIMENTAL
Intervention: 67% NaHCO3 toothpaste
Number of subjects: 246
Study 29758155 — intervention group
Group type: COMPARATOR
Intervention: 0% NaHCO3 toothpaste
Number of subjects: 246
Study 26865074 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal supplementation with folic acid, iron‐folic acid, and multiple micronutrients
Number of subjects: 834
Study 24499206 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio feedback during stair-climbing therapy
Number of subjects: 17
Study 23281332 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral self-help program
Number of subjects: 82
Study 23281332 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 82
Study 20838049 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary percutaneous gastric electrical stimulation (TPGES) with low current settings (5-7 mA) for 7-21 days.
Number of subjects: 27
Study 20838049 — intervention group
Group type: COMPARATOR
Intervention: TPGES ON period (12-14 days) compared to OFF period (12-14 days).
Number of subjects: 27
Study 20838049 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased stimulation (8-10 mA) for nonresponders for an additional 14-21 days.
Number of subjects: 27
Study 20838049 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent GES implant after TPGES.
Number of subjects: 27
Study 18973936 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (1 mg twice daily)
Number of subjects: 238
Study 18973936 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (4 mg daily)
Number of subjects: 238
Study 18973936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 16159895 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 22
Study 12624285 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g over 30 minutes)
Number of subjects: 42
Study 10831521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold-coated Inflow stent
Number of subjects: 731
Study 10831521 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Inflow stainless steel stent
Number of subjects: 731
Study 9987642 — intervention group
Group type: COMPARATOR
Intervention: Forearm vascular resistance during semierect exercise
Number of subjects: 42
Study 9987642 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements during erect treadmill exercise
Number of subjects: 42
Study 9987642 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated, cardiopulmonary, and carotid baroreceptor sensitivity
Number of subjects: 42
Study 9987642 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in forearm vascular resistance on day 28
Number of subjects: 42
Study 7874862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 12 hours
Number of subjects: 19
Study 7874862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 36 hours
Number of subjects: 19
Study 7874862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 72 hours
Number of subjects: 19
Study 7874862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (duration not specified)
Number of subjects: 19
Study 3277578 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient Family Intervention
Number of subjects: 169
Study 3277578 — intervention group
Group type: COMPARATOR
Intervention: Comparison treatment (hospitalization without family intervention)
Number of subjects: 169
Study 31992358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation (PFR) program
Number of subjects: 128
Study 31992358 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (lifestyle advice, pharmacotherapy with bulking agents or antidiarrheal medication)
Number of subjects: 128
Study 29714527 — intervention group
Group type: EXPERIMENTAL
Intervention: Secured ETT
Number of subjects: 5
Study 29714527 — intervention group
Group type: EXPERIMENTAL
Intervention: Secured LMA
Number of subjects: 5
Study 29714527 — intervention group
Group type: EXPERIMENTAL
Intervention: Secured King
Number of subjects: 5
Study 29714527 — intervention group
Group type: EXPERIMENTAL
Intervention: Secured iGel
Number of subjects: 5
Study 29714527 — intervention group
Group type: COMPARATOR
Intervention: Unsecured ETT
Number of subjects: 5
Study 29714527 — intervention group
Group type: COMPARATOR
Intervention: Unsecured LMA
Number of subjects: 5
Study 29714527 — intervention group
Group type: COMPARATOR
Intervention: Unsecured King
Number of subjects: 5
Study 29714527 — intervention group
Group type: COMPARATOR
Intervention: Unsecured iGel
Number of subjects: 5
Study 29714527 — intervention group
Group type: COMPARATOR
Intervention: Comparison of secured vs unsecured devices
Number of subjects: 5
Study 29714527 — intervention group
Group type: COMPARATOR
Intervention: Secured King vs secured ETT
Number of subjects: 5
Study 29714527 — intervention group
Group type: COMPARATOR
Intervention: Secured iGel vs secured ETT
Number of subjects: 5
Study 27977637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (Tic)
Number of subjects: 166
Study 27977637 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (Clo)
Number of subjects: 166
Study 25286912 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral foundation-based frames (harm, fairness, ingroup, authority, purity)
Number of subjects: 0
Study 22253271 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner presence during epidural catheter insertion (partner-in group)
Number of subjects: 84
Study 22253271 — intervention group
Group type: COMPARATOR
Intervention: No partner presence during epidural catheter insertion (partner-out group)
Number of subjects: 84
Study 20361901 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex extended release (ER) at 15 mg/kg/d titrated to a maximum of 30 mg/kg/d
Number of subjects: 60
Study 20361901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18403559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous rtPA
Number of subjects: 63
Study 18403559 — intervention group
Group type: COMPARATOR
Intervention: Control (no intravenous rtPA)
Number of subjects: 63
Study 15999153 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating B cells in invasive ductal carcinoma (IDC)
Number of subjects: 0
Study 15999153 — intervention group
Group type: COMPARATOR
Intervention: Tumor-infiltrating B cells in medullary breast carcinoma (MBC)
Number of subjects: 0
Study 11936572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with orange juice
Number of subjects: 15
Study 11936572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with calcium-fortified orange juice
Number of subjects: 15
Study 11936572 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin with water
Number of subjects: 15
Study 11936572 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin with calcium-fortified orange juice vs orange juice
Number of subjects: 15
Study 8829858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 0.4 mg.kg‐1 iv, repeated three times at six hour intervals
Number of subjects: 60
Study 8829858 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 1.0 mg.kg‐1 iv after general anaesthesia induction and 1.0 mg.kg‐1 after 12 hr
Number of subjects: 60
Study 2809260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular gentamicin therapy
Number of subjects: 21
Study 2809260 — intervention group
Group type: COMPARATOR
Intervention: Intravenous antibiotics alone
Number of subjects: 21
Study 51409 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with live vaccinia virus 14 days before wide local excision
Number of subjects: 48
Study 51409 — intervention group
Group type: COMPARATOR
Intervention: Wide local excision of the primary melanoma
Number of subjects: 48
Study 31790151 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin added to adjuvant chemotherapy
Number of subjects: 880
Study 31790151 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to adjuvant chemotherapy
Number of subjects: 880
Study 28653324 — intervention group
Group type: EXPERIMENTAL
Intervention: Needling
Number of subjects: 60
Study 28653324 — intervention group
Group type: COMPARATOR
Intervention: Debridement
Number of subjects: 60
Study 26280855 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration tourniquet application
Number of subjects: 60
Study 26280855 — intervention group
Group type: COMPARATOR
Intervention: Standard duration tourniquet application
Number of subjects: 60
Study 24016014 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.08% target blood alcohol concentration)
Number of subjects: 0
Study 24016014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24016014 — intervention group
Group type: COMPARATOR
Intervention: No-alcohol control
Number of subjects: 0
Study 21654128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA)
Number of subjects: 28237
Study 21654128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28237
Study 21654128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA) in high-risk group
Number of subjects: 28237
Study 21654128 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA) in low-risk group
Number of subjects: 28237
Study 19134042 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoxy resin-based sealer
Number of subjects: 120
Study 19134042 — intervention group
Group type: EXPERIMENTAL
Intervention: UDMA resin-based sealer
Number of subjects: 120
Study 19134042 — intervention group
Group type: COMPARATOR
Intervention: Sound dentine
Number of subjects: 120
Study 19134042 — intervention group
Group type: COMPARATOR
Intervention: Prepared dentine
Number of subjects: 120
Study 17892526 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 28
Study 17892526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 15577415 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype/virtual phenotype (vPt)
Number of subjects: 303
Study 15577415 — intervention group
Group type: COMPARATOR
Intervention: Real phenotype (rPt)
Number of subjects: 303
Study 11510871 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% below average power output TT
Number of subjects: 13
Study 11510871 — intervention group
Group type: COMPARATOR
Intervention: 15% above average power output TT
Number of subjects: 13
Study 11510871 — intervention group
Group type: COMPARATOR
Intervention: Self-selected pace TT (SS)
Number of subjects: 13
Study 9927886 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program on hypertension
Number of subjects: 150
Study 9927886 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 150
Study 7923842 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics added to treatment by sinus lavage
Number of subjects: 79
Study 7923842 — intervention group
Group type: COMPARATOR
Intervention: Sinus lavage without antibiotics
Number of subjects: 79
Study 7923842 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral opaque sinus radiographs
Number of subjects: 79
Study 7923842 — intervention group
Group type: EXPERIMENTAL
Intervention: Branhamella catarrhalis cultured
Number of subjects: 79
Study 3361421 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive recall of ex-spouse (PS)
Number of subjects: 60
Study 3361421 — intervention group
Group type: COMPARATOR
Intervention: Conflictual recall of ex-spouse (C)
Number of subjects: 60
Study 3361421 — intervention group
Group type: COMPARATOR
Intervention: Positive recall of a friend (PF)
Number of subjects: 60
Study 406098 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isosorbide dinitrate (ISDN) 29 mg
Number of subjects: 19
Study 406098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 19
Study 406098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31812702 — intervention group
Group type: EXPERIMENTAL
Intervention: Astodrimer 1% Gel
Number of subjects: 255
Study 31812702 — intervention group
Group type: COMPARATOR
Intervention: Placebo Gel
Number of subjects: 255
Study 31299067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted darunavir monotherapy for 48 weeks
Number of subjects: 81
Study 31299067 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher VAS-measured adherence
Number of subjects: 81
Study 31299067 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable HIV-1 DNA RAMs
Number of subjects: 81
Study 28006055 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficient MMR tumors
Number of subjects: 1395
Study 28006055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant BRAFV600E tumors
Number of subjects: 1395
Study 28006055 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutant KRAS tumors
Number of subjects: 1395
Study 28006055 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficient MMR tumors of the proximal colon
Number of subjects: 1395
Study 28006055 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal colon tumors with mutant KRAS in codon 12
Number of subjects: 1395
Study 28006055 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal colon tumors with mutant KRAS in codon 13
Number of subjects: 1395
Study 26097039 — intervention group
Group type: EXPERIMENTAL
Intervention: ustekinumab 45 mg
Number of subjects: 615
Study 26097039 — intervention group
Group type: EXPERIMENTAL
Intervention: ustekinumab 90 mg
Number of subjects: 615
Study 26097039 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 615
Study 26097039 — intervention group
Group type: EXPERIMENTAL
Intervention: ustekinumab 45 mg and 90 mg
Number of subjects: 615
Study 26097039 — intervention group
Group type: EXPERIMENTAL
Intervention: ustekinumab
Number of subjects: 615
Study 23907381 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia (8, 20 and 40 mU m(-2) min(-1))
Number of subjects: 20
Study 23907381 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia
Number of subjects: 20
Study 22230809 — intervention group
Group type: EXPERIMENTAL
Intervention: colestimide 4g/day (T group, n=23)
Number of subjects: 43
Study 22230809 — intervention group
Group type: COMPARATOR
Intervention: continuation of current therapy (C group, n=20)
Number of subjects: 43
Study 20716842 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/HCT
Number of subjects: 20
Study 20716842 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan/HCT
Number of subjects: 20
Study 20716842 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 20
Study 17418428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine and atropine intramuscularly (group K, n=50)
Number of subjects: 100
Study 17418428 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine, atropine and midazolam intramuscularly (group KM, n=50)
Number of subjects: 100
Study 15842550 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg morphine sulphate (M)
Number of subjects: 12
Study 15842550 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oxycodone hydrochloride (O)
Number of subjects: 12
Study 15842550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination M10/O5
Number of subjects: 12
Study 15842550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination M7.5/O7.5
Number of subjects: 12
Study 15842550 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination M5/O10
Number of subjects: 12
Study 15842550 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study 12498544 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at WBGT of 22.5 degrees C
Number of subjects: 7
Study 12498544 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at WBGT of 26.5 degrees C
Number of subjects: 7
Study 12498544 — intervention group
Group type: COMPARATOR
Intervention: Exercise conducted during the preceding afternoon
Number of subjects: 7
Study 12498544 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exercise bouts on successive days
Number of subjects: 7
Study 15168720 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily didanosine (ddI)
Number of subjects: 0
Study 15168720 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily stavudine (d4T) plus once-daily ddI
Number of subjects: 0
Study 15168720 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7808252 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtraining group (OT) - exercised daily for 2 weeks at 100% of 1 RM
Number of subjects: 17
Study 7808252 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) - exercised 1 day/week at 50% of 1 RM
Number of subjects: 17
Study 7808252 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtraining group (OT)
Number of subjects: 17
Study 2780876 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of chlorpromazine (CPZ)
Number of subjects: 16
Study 2780876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 413639 — intervention group
Group type: EXPERIMENTAL
Intervention: Serogroup A meningococcal polysaccharide vaccine
Number of subjects: 176646
Study 413639 — intervention group
Group type: COMPARATOR
Intervention: Tetanus toxoid
Number of subjects: 176646
Study 31180512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) + oral EPAP
Number of subjects: 22
Study 31180512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) + oral/nasal EPAP
Number of subjects: 22
Study 31180512 — intervention group
Group type: COMPARATOR
Intervention: Mandibular advancement splint (MAS) alone
Number of subjects: 22
Study 28029308 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integrated palliative care (PC)
Number of subjects: 350
Study 28029308 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study 25468945 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 2072
Study 25468945 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 2072
Study 25468945 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg and 300 mg
Number of subjects: 2072
Study 25468945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2072
Study 24118671 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg lomitapide on Day 1 followed by 200 mg on Day 3
Number of subjects: 56
Study 24118671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg BID
Number of subjects: 56
Study 24118671 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg moxifloxacin on Day 3
Number of subjects: 56
Study 24118671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 21795553 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS for 5 days
Number of subjects: 0
Study 21795553 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days rTMS to motor cortex
Number of subjects: 0
Study 19459475 — intervention group
Group type: EXPERIMENTAL
Intervention: Grifor vaccine
Number of subjects: 300
Study 19459475 — intervention group
Group type: COMPARATOR
Intervention: Vaxigrip vaccine
Number of subjects: 300
Study 16321485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hop extract (100 microg 8‐PN)
Number of subjects: 67
Study 16321485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hop extract (250 microg 8‐PN)
Number of subjects: 67
Study 16321485 — intervention group
Group type: EXPERIMENTAL
Intervention: Hop extract (100 microg and 250 microg 8‐PN)
Number of subjects: 67